Company intelligence / Profile preview

Pharmalectin India

Rangareddy, Telangana, India

Ownership: Private
Development stage: Other

Overview

Pharmalectin India is an Indian private limited pharmaceutical subsidiary established by Bioxytran to support commercialization of ProLectin-M in India. Publicly available information indicates the entity was incorporated in August 2022, is active, and is registered in Telangana, India. Its stated purpose is to launch commercial sales of ProLectin-M in India if regulatory approval is obtained from the Central Drugs Standard Control Organization. The operating focus appears tied to Bioxytran's galectin-antagonist antiviral program rather than an independent multi-asset pipeline. Available records describe the company as an unlisted private company with a small capital base and limited standalone public disclosure.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculePolysaccharide therapy
Industry: Biotech

Beyond the preview

Go deeper on Pharmalectin India.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharmalectin India.

Explore the full profile